Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Aug 1;54(4):343–351. doi: 10.1097/QAI.0b013e3181deaf4d

TABLE 4.

Cox proportional hazards analyses for HIV NRD development in European American and African American patients

European Americans
 African Americans
Gene/haplotype SNP events/n HR (95% CI) P events/n HR (95% CI) P
RANTES-403A rs2107538 48/299 0.67 (0.37–1.24) 0.21 49/198 1.09 (0.48–2.46) 0.84
RANTES-28G rs2280788 0/239 - - - 52/219 1.78 (0.24–13.19) 0.57
RANTES-In1.1C rs2280789 50/329 0.53 (0.26–1.10) 0.09 52/218 2.56 (1.40–4.68) 0.002
        H1(G-C-T) 50/328 0.69 (0.21–2.30) 0.55 52/218 1.08 (0.59–1.96) 0.81
        H2(A-C-T) 50/328 1.28 (0.57–2.91) 0.55 52/218 0.55 (0.31–0.99) 0.04
        H3(A-C-C) 50/328 0.56 (0.27–1.16) 0.11 52/218 2.72 (1.48–5.00) 0.001
IL-10-5A` rs1800872 49/330 2.07 (1.18–3.63) 0.01a 52/219 1.28 (0.72–2.27) 0.40
            HG1 49/329 2.09 (1.19–3.67) 0.01a 48/207 1.31 (0.72–2.37) 0.38
            HG2 49/329 0.71 (0.51–1.58) 0.90 48/207 0.99 (0.55–1.77) 0.97
            HG3 49/329 0.76 (0.42–1.36) 0.35 48/207 1.33 (0.73–2.40) 0.35
a

When each eye is considered separately, IL-10-5A` HR=2.46, P = 0.0002; IL-10 HG1 haplotype HR=2.44, P = 0.0002 in European Americans.